The purpose of this study was to evaluate serum levels of OPG, soluble RANKL (sRANKL), the ratio sRANKL/OPG, VEGF, HGF, and known factors of disease activity at diagnosis and in plateau phase and to estimate the effect of treatment on their circulating levels in patients with MM. The gene discussed is TNFSF11; the disease is Miyoshi myopathy.